ARTICLE | Clinical News

Interferon-alpha: Phase II

March 13, 2000 8:00 AM UTC

AMAR said that its 89-patient, 3-month U.S. Phase II trial failed to show a statistically significant benefit of 150 IU/day or 50 IU/day interferon alpha in reducing morning stiffness associated with fibromyalgia compared to placebo. All three groups reported a reduction in morning stiffness in muscle, tendons and ligaments, and the improvement was most pronounced in the 50 IU/day group. AMAR noted that a greater placebo response rate was seen in the trial than had been previously observed. ...